《新股消息》赛生药业(06600.HK)公开超购1,067倍 一手中签率仅3%
赛生药业(06600.HK)公布招股结果,计划发行近1.16亿股,原先其中10%为本地公开发售,公开发售超购1,067.05倍,由於相关超购100倍以上,经重新分配後,公开发售股数增至50%,而国际发售项下初步提呈已获超额认购约10倍。一手500股中签率为3%,认购7万股(或140手)才可稳获分配一手。
每股发售价定於18.8元,为上限定价(招股价介乎每股17.2至18.8元),公司预计,所得款项净额为20.4亿元,当中约30%用於投资中国或其他全球市场的潜在收购及授权;约28%将用於偿还现有债务;约26%用於开发及商业化临床阶段候选产品;10%将用於招聘、扩大销售与营销网络以及商业及开发基础设施;余下约6%为持续临床研究提供资金。
是次招股引入11名基石投资者,包括Shanghai Pharmaceutical Lin-gang Special Area、Daguan International、China Post and Capital Global Asset Management等,合共认购5,513万股股份,占紧随全球发售完成後公司已发行股本的约8.13%。
该股将於明日(3日)上市,摩根士丹利、中金及瑞信为联席保荐人。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.